Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 439

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Open access
Zeuzem, Stefan, Foster, Graham R., Wang, Stanley, Asatryan, Armen, Gane, Edward, Feld, Jordan J., Asselah, Tarik, Bourlière, Marc, Ruane, Peter J., Wedemeyer, Heiner, Pol, Stanislas, Flisiak, Robert, Poordad, Fred, Chuang, Wan-Long, Stedman, Catherine A., Flamm, Steven, Kwo, Paul, Dore, Gregory J., Sepulveda-Arzola, Gladys, Roberts, Stuart K., Soto-Malave, Ruth, Kaita, Kelly, Puoti, Massimo, Vierling, John, Tam, Edward, Vargas, Hugo E., Bruck, Rafi, Fuster, Francisco, Paik, Seung-Woon, Felizarta, Franco, Kort, Jens, Fu, Bo, Liu, Ran, Ng, Teresa I., Pilot-Matias, Tami, Lin, Chih-Wei, Trinh, Roger, Mensa, Federico J.·2018·New England Journal of Medicine

Abstract

BACKGROUND: Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week and 12-week courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. METHODS: We conducted two phase 3, randomized, open-label, multicenter trials. Patients with genotype 1 infection were randomly assigned in a 1:1 ratio to receive once-daily glecaprevir-pibrentasvir for either 8 or 12 weeks. Patients with genotype 3 infection were randomly assigned in a 2:1 ratio to receive 12 weeks of treatment with either glecaprevir-pibrentasvir or sofosbuvir-daclatasvir. Additional patients with genotype 3 infection were subsequently enrolled and nonrandomly assigned to receive 8 weeks of treatment with glecaprevir-pibrentasvir. The primary end point was the rate of sustained virologic response 12 weeks after the end of treatment. RESULTS: In total, 1208 patients were treated. The rate of sustained virologic response at 12 weeks among genotype 1-infected patients was 99.1% (95% confidence interval [CI], 98 to 100) in the 8-week group and 99.7% (95% CI, 99 to 100) in the 12-week group. Genotype 3-infected patients who were treated for 12 weeks had a rate of sustained virologic response at 12 weeks of 95% (95% CI, 93 to 98; 222 of 233 patients) with glecaprevir-pibrentasvir and 97% (95% CI, 93 to 99.9; 111 of 115) with sofosbuvir-daclatasvir; 8 weeks of treatment with glecaprevir-pibrentasvir yielded a rate of 95% (95% CI, 91 to 98; 149 of 157 patients). Adverse events led to discontinuation of treatment in no more than 1% of patients in any treatment group. CONCLUSIONS: Once-daily treatment with glecaprevir-pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among patients with HCV genotype 1 or 3 infection who did not have cirrhosis. (Funded by AbbVie; ENDURANCE-1 and ENDURANCE-3 ClinicalTrials.gov numbers, NCT02604017 and NCT02640157 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1702417

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 439

Metadata

Authors
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., Asselah, T., Bourlière, M., Ruane, P. J., Wedemeyer, H., Pol, S., Flisiak, R., Poordad, F., Chuang, W.-L., Stedman, C. A., Flamm, S., Kwo, P., Dore, G. J., Sepulveda-Arzola, G., Roberts, S. K., Soto-Malave, R., Kaita, K., Puoti, M., Vierling, J., Tam, E., Vargas, H. E., Bruck, R., Fuster, F., Paik, S.-W., Felizarta, F., Kort, J., Fu, B., Liu, R., Ng, T. I., Pilot-Matias, T., Lin, C.-W., Trinh, R., & Mensa, F. J.
Venue
New England Journal of Medicine
Published
2018-01-25
Volume
378
Issue
4
Pages
354-369
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2788216918
Cited by
439
References
17
FWCI
38.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. https://app.cochat.ai/papers/10.1056/nejmoa1702417
The paper
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., Asselah, T., Bourlière, M., Ruane, P. J., Wedemeyer, H., Pol, S., Flisiak, R., Poordad, F., Chuang, W.-L., Stedman, C. A., Flamm, S., Kwo, P., Dore, G. J., Sepulveda-Arzola, G., . . . Mensa, F. J. (2018). Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1702417

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.